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CalciumPatients with long-chain 3-hydroxy-acyl-CoA dehydrogenase (LCHAD) deﬁciency commonly present liver dys-
function whose pathogenesis is unknown. We studied the effects of long-chain 3-hydroxylated fatty acids
(LCHFA) that accumulate in LCHAD deﬁciency on liver bioenergetics using mitochondrial preparations from
young rats. We provide strong evidence that 3-hydroxytetradecanoic (3HTA) and 3-hydroxypalmitic (3HPA)
acids, the monocarboxylic acids that are found at the highest tissue concentrations in this disorder, act as meta-
bolic inhibitors and uncouplers of oxidative phosphorylation. These conclusions are based on the ﬁndings that
these fatty acids decreased ADP-stimulated (state 3) and uncoupled respiration, mitochondrial membrane
potential and NAD(P)H content, and, in contrast, increased resting (state 4) respiration. We also veriﬁed that
3HTA and 3HPAmarkedly reduced Ca2+ retention capacity and induced swelling in Ca2+-loaded mitochondria.
These effects were mediated by mitochondrial permeability transition (MPT) induction since they were totally
prevented by the classical MPT inhibitors cyclosporin A and ADP, as well as by ruthenium red, a Ca2+ uptake
blocker. Taken together, our data demonstrate that the major monocarboxylic LCHFA accumulating in LCHAD
deﬁciency disrupt energy mitochondrial homeostasis in the liver. It is proposed that this pathomechanism may
explain at least in part the hepatic alterations characteristic of the affected patients.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
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5571; fax: +55 51 3308 5540.the oxidation of long-chain fatty acids (LCFA). Deﬁciency of LCHAD
was described in 1989 [1] and is a relatively frequent fatty acid oxida-
tion defect [2]. It is biochemically characterized by accumulation of
long-chain 3-hydroxylated fatty acids (LCHFA) in body ﬂuids and
tissues, as well as by episodes of lactic acidemia and hypoketotic hypo-
glycemia, particularly during periods of intense catabolism, such as
prolonged fasting and infections [3–6]. The clinical manifestations of
LCHAD deﬁciency are more severe than the β-oxidation disorders of
medium and short chain fatty acids [7,8], suggesting a high toxicity for
the accumulating LCHFA. Affected patients present a wide variety of
symptoms, including severe hepatopathy and cardiomyopathy, as well
as retinopathy, hypotonia, peripheral neuropathy, speech and develop-
mental delay, lethargy and seizures [9,10].
Hepatic dysfunction is a common ﬁnding in LCHAD deﬁciency,
especially during episodes of metabolic decompensation, which are
characterized by hypoketosis hypoglycemia, hyperlactic acidemia and
lethargy [11]. Most patients present hepatomegaly, acute cholestatic
621F.H. Hickmann et al. / Biochimica et Biophysica Acta 1847 (2015) 620–628jaundice, massive hepatic necrosis and hepatic steatosis accompanied
by ﬁbrosis [12–14].
Treatment is based on dietary fat restriction, fasting avoidance, night
feeds, as well as supplementation of essential fatty acids and medium
chain triglycerides [15–18].
The pathophysiology of tissue damage in LCHAD deﬁciency is
still unclear, but may possibly be associated with hypoglycemia and
hypoketonemia leading to energy deprivation. Therefore, since liver es-
sentially utilizes fatty acids for most of its energetic needs, the hepatic
symptomatology of LCHAD deﬁciency may involve low energy produc-
tion from fatty acids and/or alternatively due to the toxicity of LCHFA or
their long-chain 3-hydroxyacylcarnitines derivatives that accumulate in
this disorder [19–22]. Noteworthy, hyperlactic acidemia associatedwithFig. 1. Effects of 3-hydroxytetradecanodioic (3HTDA), 3-hydroxytetradecanoic (3HTA) and 3-
uncoupled (CCCP-stimulated) (D) respiration, as well as respiratory control ratio (RCR) (C), u
of 3HTA (100 μM) on resting (state 4) respiration in the presence of atractyloside (ATC, 30 μM)
(0.75 mg protein·mL−1) and 3HTDA, 3HTA or 3HPA (10–100 μM) were added to the incubatio
acids and ethanol (the ﬁnal concentration of EtOH in the incubation medium was 1%) was adde
200 μM EGTA. Values are means ± standard deviation for three to six independent experim
ofprotein−1]: 69.02±11.94; (B) [nmolO2·min−1·mg ofprotein−1]: 14.62±3.58; (C) [RCR] 4.9
of protein−1]: 13.51 ± 2.66; (F) [nmol O2·min−1·mg of protein−1]: 11.92 ± 2.56). *P b 0.05,
multiple range test).abnormal mitochondrial morphology with swollen appearance and fat
inﬁltration observed in these patients indicates a role for mitochondrial
energy disruption in its ethiopathogenesis [23]. Recent experimental
studies demonstrating that the monocarboxylic LCHFA accumulating
in LCHADdeﬁciency provoke impairment ofmitochondrial bioenergetics
in forebrain and heart of young rats, strengthen this hypothesis [24,25].
In a further report, it was demonstrated that LCHFA induce mito-
chondrial permeability transition (MPT) in Ca2+-loaded brain mito-
chondria [26]. These data provide unequivocal evidence that LCHFA
disturb energy mitochondrial homeostasis in brain and heart. How-
ever, to the best of our knowledge, there is no work evaluating mito-
chondrial function in liver exposed to the LCHFA accumulating in
LCHAD deﬁciency.hydroxypalmitic (3HPA) acids on ADP-stimulated (state 3) (A), resting (state 4) (B), and
sing glutamate/malate as substrate in liver mitochondria. Panels E and F show the effects
and guanosine diphosphate (GDP, 200 μM), respectively. The mitochondrial preparations
n medium in the beginning of the assays. Controls were performed in the absence of fatty
d to the incubation medium in the beginning of the assays. The reaction media contained
ents and are expressed as percentage of control (Controls: (A) [nmol O2·min−1·mg
5±1.12; (D) [nmolO2·min−1·mg of protein−1]: 53.40±13.18; (E) [nmolO2·min−1·mg
**P b 0.01, ***P b 0.001, compared to controls. ###P b 0.001, compared to HTA (Duncan's
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hydroxytetradecanodioic (3HTDA), 3-hydroxytetradecanoic (3HTA)
and 3-hydroxypalmitic (3HPA) acids on important parameters of mito-
chondrial bioenergetics, namely the respiratory states 3 and 4, respira-
tory control ratio (RCR) and uncoupled respiration, as well as the
mitochondrial membrane potential (ΔΨm), swelling, Ca2+ retention
capacity and NAD(P)H content in liver mitochondrial preparations
from young rats in the presence or absence of Ca2+ in the hopes to
clarify the mechanisms of toxicity of these compounds.
2. Material and methods
2.1. Reagents
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO,
USA), except for 3HTDA (96% purity), which was synthesized by
Dr. Ernesto Brunet, from Universidad Autonoma de Madrid. Stock
solutions of a racemic mixture (DL) of 3HTDA, 3HTA and 3HPA were
prepared in ethanol (EtOH) to dissolve the fatty acids and added to
incubation medium at ﬁnal concentrations of 10–100 μM. The ﬁnal
concentration of EtOH in the incubation medium was 1%. The same
percentage of EtOH was present in controls and proved not to alter
per se the parameters evaluated.
2.2. Animals
Thirty-day-old Wistar rats obtained from our breeding colony were
used. The animals were maintained on a 12:12 h light/dark cycle in
air-conditioned constant temperature (22 ± 1 °C) colony room, withFig. 2. Effects of 3-hydroxytetradecanoic (3HTA) and 3-hydroxypalmitic (3HPA) acids on
(D) respiration, as well as respiratory control ratio (RCR) (C), using succinate as substrate plu
and various concentrations of 3HTA or 3HPA (10–100 μM) were added to the incubation med
and ethanol (the ﬁnal concentration of EtOH in the incubation medium was 1%) was added
200 μM EGTA. Values are means ± standard deviation for three independent experiments and
125.60 ± 8.21; (B) [nmol O2·min−1·mg of protein−1]: 34.55 ± 3.91; (C) [RCR] 3.66 ± 0.43; (D
compared to controls (Duncan's multiple range test).free access to water and 20% (w/w) protein commercial chow. This
study was performed in strict accordance with the Guide for the Care
and Use of Laboratory Animals (eighth edition, 2011) and approved
by the Ethical Committee of the Federal University of Rio Grande do
Sul, Porto Alegre, Brazil. All efforts were also made to use the minimal
number of animals necessary to produce reliable scientiﬁc data. The
manuscript does not contain clinical studies or patient data.2.3. Preparation of mitochondrial fractions
Mitochondrial preparations from liver were isolated according to
Mirandola [27], with modiﬁcations. Animals were sacriﬁced by decapi-
tation, and the liver was removed and homogenized with a glass hand-
held homogenizer in ice-cold mitochondria isolation medium contain-
ing 225 mM mannitol, 75 mM sucrose, 1 mM EGTA, 0.1% bovine
serum albumin (BSA, free fatty acid) and 10 mM HEPES, pH 7.2. The
homogenate was centrifuged at 2000 ×g for 3 min at 4 °C. The pellet
was discarded and the supernatant was centrifuged at 12,000 ×g for
10min at 4 °C. The resultant pellet was resuspended in 5mL of isolation
mediumwithout EGTA and centrifuged at 12,000 ×g for 10 min at 4 °C.
The ﬁnal pellet was resuspended in isolation medium without EGTA in
an approximate protein concentration of 30mg·mL−1. Protein concen-
tration was measured by the method of Bradford [28], using BSA as
standard. Mitochondria obtained from liver were used in the assays
immediately after isolation and assays were carried out in the
absence or presence of Ca2+. In some experiments, we used mito-
chondria from forebrain whose preparation was similar to the liver
[27].ADP-stimulated (state 3) (A), resting (state 4) (B) and uncoupled (CCCP-stimulated)
s rotenone in liver mitochondria. The mitochondrial preparations (0.5 mg protein·mL−1)
ium in the beginning of the assays. Controls were performed in the absence of fatty acids
to the incubation medium in the beginning of the assays. The reaction media contained
are expressed as percentage of control (Controls: (A) [nmol O2·min−1·mg of protein−1]:
) [nmol O2·min−1·mg of protein−1]: 116.75 ± 17.95). *P b 0.05, **P b 0.01, ***P b 0.001,
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consumption
The rate of oxygen consumption was measured polarographically
using a Clark-type electrode in a thermostatically controlled (37 °C)
and magnetically stirred incubation chamber. 3HTDA, 3HTA or 3HPA
(10–100 μM) was added to the reaction medium at the beginning of
the assay. The assay was performed with mitochondrial preparations
(0.75 mg protein−1·mL−1 when using 2.5 mM glutamate plus
2.5 mMmalate as substrates and 0.5 mg protein−1·mL−1 when using
5 mM succinate as substrate plus 4 μM rotenone) and incubated for
60 s in a buffer containing 100 mM sucrose, 65mM potassium chloride,
10mMHEPES, 1 mMKH2PO4 and 200 μMEGTA, pH 7.2. State 3 respira-
tion was measured after addition of 1 mM ADP to the incubation medi-
um and uncoupled respiration after addition of 3 μM CCCP. To measureFig. 3. Effects of 3-hydroxytetradecanodioic (3HTDA), 3-hydroxytetradecanoic (3HTA) and 3-h
and F) or absence (E) of Ca2+ in liver (A–E) and brain (F) mitochondria. All experiments
protein·mL−1) supported by glutamate/malate or succinate. (A) 3HTDA, 3HTA or 3HPA (30
lines b–d). (C) 3HTA (30 μM, lines b–f), ruthenium red (RR, 5 μM, line c), cyclosporin A
ethylmaleimide (NEM, 20 μM) (line f) was added in the beginning of the assay. (D) 3HTA (3
(300 μM) (line d) and guanosine diphosphate (GDP, 200 μM, line e) were added in the be
(100 μM, lines d). (F) 3HTA (30 μM, lines b–e). ruthenium red (RR, 1 μM, line c), cyclosporin A
e) were added in the beginning of the assay. Controls (lines a) were performed in the absenc
30 μM Ca2+ 150 s after the beginning of the assay, as indicated, whereas in panel E there
(E) EGTA. CCCP (3 μM) was added in the end of the assays. Traces are representative of three
(FAU). ***P b 0.001, compared to controls (Duncan's multiple range test).resting (state 4) respiration, 1 μg·mL−1 oligomycin A was added to the
incubation medium. In some experiments, guanosine diphosphate
(GDP, 200 μM) and atractyloside (ATC, 30 μM)were added to the mito-
chondrial preparations. The RCR (state 3/state 4) was then calculated.
States 3 and 4 were expressed as nmol O2 consumed·min−1·mg
protein−1. Only mitochondrial preparations with RCR greater than 3
were used in the experiments.
2.5. Experimental procedures for the spectroﬂuorimetric and
spectrophotometric assays
Measurements of ΔΨm, NAD(P)H content and Ca2+ retention
capacity were performed using spectroﬂuorimetry, whereas mitochon-
drial swelling was measured by spectrophotometry. Mitochondrial in-
cubations were carried out at 37 °C, with continuous magnetic stirringydroxypalmitic (3HPA) acids onmitochondrial membrane potential in the presence (A–D
were performed in a reaction media containing mitochondrial preparations (0.5 mg
μM, lines b–d) were added 50 s after the beginning of the assay. (B) 3HTA (10–30 μM,
(CsA, 1 μM) plus ADP (300 μM) (line d), dithiothreitol (DTT, 5 mM) (line e) or N-
0 μM, lines b–e), ruthenium red (RR, 1 μM, line c), cyclosporin A (CsA, 1 μM) plus ADP
ginning of the assay. (E) 3HTDA (100 μM, lines b), 3HTA (100 μM, lines c) and 3HPA
(CsA, 1 μM) plus ADP (300 μM) (line d) and guanosine diphosphate (GDP, 200 μM, line
e of fatty acids. Panels A–D and F refer to mitochondrial preparations supplemented by
was no exogenous Ca2+. The reaction media contained 30 μM (A–D and F) or 100 μM
independent experiments (animals) and were expressed as ﬂuorescence arbitrary units
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oligomycin A (resting respiration) using mitochondria (0.5 mg
protein·mL−1) supported by 2.5 mM glutamate plus 2.5 mM malate
or 5 mM succinate plus 4 μM rotenone. 3HTDA (30–100 μM), 3HTA
(10–100 μM), 3HPA (10–100 μM), CaCl2 (20–40 μM), CCCP (3 μM) and
alamethicin (Alm, 40 μg·mL−1) were added as indicated by the arrows
in the ﬁgures. In some experiments, ruthenium red (RR, 5 μM), cyclo-
sporin A (CsA, 1 μM), ADP (300 μM), dithiothreitol (DTT, 5 mM),
N-ethylmaleimide (20 μM, NEM) and GDP (200 μM) were added in
the assay. Traces are representative of independent experiments carried
out in mitochondrial preparations from liver of three animals and were
expressed as arbitrary units, unless otherwise stated. Statistical analyses
were also carried out by analyzingquantitatively the data obtained from
the assays.
2.6. Mitochondrial membrane potential (ΔΨm)
The ΔΨmwas estimated according to Akerman and Wikstrom [29]
and Figueira and collaborators [30] in a medium containing 150 mM
KCl, 5 mM MgCl2, 0.1 mg·mL−1 BSA, 5 mM HEPES, 2 mM KH2PO4, 30
or 100 μMEGTA, pH 7.2. The ﬂuorescence of 5 μMcationic dye safranine
O, a ΔΨm indicator, was followed at excitation and emission wave-
lengths of 495 and 586 nm. CCCP was added in the end of measure-
ments to abolish ΔΨm.
2.7. Mitochondrial NAD(P)H
Mitochondrial matrix NAD(P)H ﬂuorescence was measured at
366 nm excitation and 450 nm emission wavelengths, in a medium
containing 150 mM KCl, 5 mM MgCl2, 0.1 mg·mL−1 BSA, 5 mM
HEPES, 2 mM KH2PO4, 30 or 100 μM EGTA, pH 7.2. CCCP was added in
the end of the measurements to induce maximal NAD(P)H oxidation.Fig. 4. Effects of 3-hydroxytetradecanodioic (3HTDA), 3-hydroxytetradecanoic (3HTA) and 3-h
absence (D) of Ca2+. All experiments were performed in a reaction media containing mitocho
(A) 3HTDA, 3HTA or 3HPA (30 μM, lines b–d) was added 50 s after the beginning of the assa
1 μM) plus ADP (300 μM) (line d) were added in the beginning of the assay. (C) 3HTA (30 μ
(300 μM) (line d)were added in the beginning of the assay. (D) 3HTDA (100 μM, line b), 3HTA (1
of fatty acids. Panels A–C refer tomitochondrial preparations supplemented by 30 μMCa2+ 150
Ca2+. The reaction media contained 30 μM (A–C) or 100 μM (D) EGTA. CCCP (3 μM) was add
(animals) and were expressed as ﬂuorescence arbitrary units (FAU). ***P b 0.001, compared to2.8. Mitochondrial swelling
Mitochondrial swelling was determined in 96-well plates as the
decrease in the turbidity of the mitochondrial suspension measured
at 540 nm wavelength using a SpectraMax M5 microplate reader, in
a medium (ﬁnal volume: 250 μL) containing 125 mM sucrose,
65 mM KCl, 2 mM K2HPO4, 1 mM MgCl2, 0.1 mg·mL−1 BSA,
10 mM HEPES, 15 μM EGTA, pH 7.2. A decrease in the turbidity
indicates an increase in mitochondrial swelling. Alamethicin
(Alm) was added in the end of the experiment to provoke maximal
swelling.2.9. Mitochondrial Ca2+ retention capacity
Ca2+ retention capacity was determined in a medium containing
150 mM KCl, 5 mM MgCl2, 0.1 mg·mL−1 BSA, 5 mM HEPES, 2 mM
KH2PO4, 10 μM EGTA, pH 7.2, following the external free Ca2+ levels
using 0.2 μMCalciumGreen-5N (Molecular Probes, Invitrogen, Carlsbad,
CA) at excitation and emission wavelengths of 506 and 532 nm, respec-
tively [31]. In the end of the measurements, maximal Ca2+ release was
induced by CCCP.2.10. Statistical analysis
Results are presented as mean ± standard deviation, unless other-
wise stated. Assays were performed in triplicate and the mean was
used for statistical analysis. Data were analyzed using one-way analysis
of variance (ANOVA) followed by the post-hoc Duncan's multiple com-
parison test when F was signiﬁcant. Differences between groups were
rated signiﬁcant at P b 0.05. All analyses were carried out using the
19.0 SPSS Statistics software.ydroxypalmitic (3HPA) acids onmitochondrial NAD(P)H content in the presence (A–C) or
ndrial preparations (0.5 mg protein·mL−1) supported by glutamate/malate or succinate.
y. (B) 3HTA (30 μM, lines b–d), ruthenium red (RR, 5 μM, line c) and cyclosporin A (CsA,
M, lines b–d). ruthenium red (RR, 1 μM, line c) and cyclosporin A (CsA, 1 μM) plus ADP
00 μM, line c) and 3HPA (100 μM, line d). Controls (lines a)were performed in the absence
s after the beginning of the assay, as indicated,whereas in panel D therewas no exogenous
ed in the end of the assays. Traces are representative of three independent experiments
controls (Duncan's multiple range test).
Fig. 5. Effects of 3-hydroxytetradecanodioic (3HTDA), 3-hydroxytetradecanoic (3HTA)
and 3-hydroxypalmitic (3HPA) acids on mitochondrial swelling in the presence of Ca2+.
All experiments were performed in a reaction media containing mitochondrial prepara-
tions (0.5 mg protein·mL−1) supported by glutamate/malate. (A) 3HTDA, 3HTA or
3HPA (30 μM, lines b–d) was added 50 s after the beginning of the assay. (B) 3HTA
(30 μM, lines b–d), ruthenium red (RR, 5 μM, line c) and cyclosporin A (CsA, 1 μM) plus
ADP (300 μM) (line d) were added in the beginning of the assay. Controls (lines a) were
performed in the absence of fatty acids. All traces refer to mitochondrial preparations
supplemented by 40 μM Ca2+ 150 s after the beginning of the assay, as indicated.
Alamethicin (Alm, 40 μg/mg of protein)was added at the end of themeasurements. Traces
are representative of three independent experiments (animals). ***P b 0.001, compared to
controls (Duncan's multiple range test).
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3.1. Long-chain monocarboxylic 3-hydroxylated fatty acids alter oxygen
consumption in liver mitochondria
The effect of the 3HTDA, 3HTA and 3HPA on liver mitochondrial
respiratory parameters measured by oxygen consumption using
glutamate plusmalate or succinate as respiratory substrateswasﬁrst in-
vestigated. 3HTA and 3HPA (50 and 100 μM) markedly increased rest-
ing (state 4) (Fig. 1B: [F(7,19) = 12.92, P b 0.001]) and decreased ADP-
stimulated (state 3) (Fig. 1A: [F(7,19) = 3.447, P b 0.05]), uncoupled res-
piration (Fig. 1D: [F(7,18) = 5.538, P b 0.01]) and RCR (Fig. 1C: [F(7,19) =
23.13, P b 0.001]) in a dose dependentmanner with glutamate plusma-
late as substrates. Similar results were obtained with succinate-
supported mitochondria (Fig. 2A: [F(6,14) = 3.054, P b 0.05]; Fig. 2B:
[F(6,14) = 16.82, P b 0.001]; Fig. 2C: [F(6,14) = 24.73, P b 0.001];
Fig. 2D: [F(6,14) = 8.095, P b 0.01]). We also veriﬁed that the 3HTA-
induced increase of resting respiration was attenuated by the competi-
tive adenine nucleotide translocator (ANT) inhibitor ATC (Fig. 1E:
[F(3,20) = 53.56, P b 0.001]), but not by the UCP inhibitor GDP (Fig. 1F:
[F(3,8) = 53.19, P b 0.001]), suggesting a role for ANT in the increase of
state 4 respiration provoked by 3HTA. In contrast, apart from a moder-
ate reduction of RCR, overall 3HTDA was not able to signiﬁcantly alter
these respiratory parameters (Fig. 1).
3.2. Long-chain monocarboxylic 3-hydroxylated fatty acids reduceΔΨm in
liver and brain mitochondria
Next, we assessed the inﬂuence of 3HTDA, 3HTA and 3HPA on ΔΨm
in liver mitochondria supported by glutamate plus malate or succinate
in order to further investigate the uncoupling action of 3HTA and
3HPA. We veriﬁed that 3HTA and 3HPA (100 μM), but not 3HTDA
(100 μM), strongly dissipated ΔΨm (Fig. 3E).
It was also observed that low concentrations of 3HTA and 3HPA
(10–30 μM) provoked a strongly dissipation of ΔΨmwhen liver mito-
chondria were challenged by Ca2+ in amediumwith low EGTA concen-
tration (Fig. 3A: [F(3,8) = 189.1, P b 0.001]; 3B: [F(3,8) = 60.78,
P b 0.001]). Furthermore, RR, an inhibitor ofmitochondrial Ca2+ uptake,
abolished the reduction of ΔΨm caused by 3HTA, emphasizing the im-
portance of Ca2+ in this effect. It can be also observed that the classical
inhibitors of MPT, CsA and ADP also protected glutamate plus malate
(Fig. 3C: [F(5,12) = 57.81, P b 0.001]) or succinate-supported (Fig. 3D:
[F(4,10) = 345.7, P b 0.001]) mitochondria against membrane depolari-
zation. In contrast, it can be seen in the ﬁgure that DTT, NEM and GDP
were not able to prevent the 3HTA-induced ΔΨm reduction, making
unlikely an oxidative attack on thiol groups of the MPT pore (Fig. 3C
and D). Finally, we found that the dicarboxylic 3HTDA did not alter
ΔΨm in the presence or absence of Ca2+ (Fig. 3A and E). Similar results
were obtained when using brain mitochondria in the same experimen-
tal conditions, although with less intense effects of 3HTA (Fig. 3F:
[F(4,10) = 302.4, P b 0.001]).
3.3. Long-chain monocarboxylic 3-hydroxylated fatty acids decrease
NAD(P)H matrix mitochondrial content in liver
In the next set of experiments we evaluated the effect of 3HTDA,
3HTA and 3HPA on mitochondrial NAD(P)H content in liver mitochon-
dria supported by glutamate plus malate or succinate. We observed
that 3HTA and 3HPA (100 μM), but not 3HTDA (100 μM), provoked a
signiﬁcant decrease of NAD(P)H levels (Fig. 4D).
In addition, 3HTA and 3HPA (30 μM) provoked a decrease of
NAD(P)H content when Ca2+ was added to themedium that contained
a low concentration of EGTA (Fig. 4A: [F(3,8) = 687.5, P b 0.001]),
suggesting that the reduced equivalents were oxidized or lost from
the matrix. Since the decrease in mitochondrial NAD(P)H content was
prevented by CsA, ADP and RR, it is conceivable that this effect may beattributed to MPT pore opening (Fig. 4B: [F(3,8) = 156.7, P b 0.001];
Fig. 4C: [F(3,8) = 137.7, P b 0.001]). Furthermore, 3HTDA, the dicarbox-
ylic analogue of 3HTA, did not change NAD(P)H content both in the
presence or absence of Ca2+ (Fig. 4A and Fig. 4D).
3.4. Long-chainmonocarboxylic 3-hydroxylated fatty acids induce swelling
in liver mitochondria
Considering that induction of MPT is classically accompanied by mi-
tochondrial swelling, we investigated the inﬂuence of 3HTDA, 3HTA and
3HPA on mitochondrial swelling in Ca2+-loaded mitochondria. It was
found that 30 μM of 3HTA and 3HPA signiﬁcantly induced swelling in
liver mitochondria supported by glutamate plus malate in the presence
of Ca2+ (Fig. 5A: [F(3,8) = 1072.0, P b 0.001]; Fig. 5B: [F(3,8) = 40.39,
P b 0.001]). Furthermore, this effect was fully prevented by RR, CsA
and ADP (Fig. 5B), indicatingMPT induction by these LCHFA. In contrast,
3HTDA did not alter this parameter (Fig. 5A).
3.5. Long-chain monocarboxylic 3-hydroxylated fatty acids reduce Ca2+
retention capacity in liver mitochondria
Since MPT induction may compromise mitochondrial Ca2+ homeo-
stasis and lead to release of this cation from themitochondria,we deter-
mined the mitochondrial Ca2+ retention capacity in the presence of
3HTDA, 3HTA or 3HPA using glutamate plusmalate or succinate as sub-
strates. It can be seen in Fig. 6A–D that 3HTA and 3HPA (10–30 μM) sig-
niﬁcantly reduced the mitochondrial Ca2+ retention capacity, an effect
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mitochondrial Ca2+ retention capacity.
4. Discussion
We demonstrated here that the major monocarboxylic LCHFA accu-
mulating in LCHAD deﬁciency (3HTA and 3HPA) disrupt mitochondrial
functions in liver of young rats at concentrations as low as 10 μM, in con-
trast to thedicarboxylate fourteen carbon chain analogue 3HTDA,which
caused no effect on all evaluated parameters. 3HPA and 3HTA impaired
liver mitochondrial bioenergetics by behaving as uncouplers, metabolic
inhibitors and MPT inductors. Mitochondrial Ca2+ retention capacity
was also compromised by these fatty acids, impairing therefore cellular
Ca2+ homeostasis.
We ﬁrst observed a decrease in state 3 and uncoupledmitochondrial
respiration caused by 3HTA and 3HPA indicating that these fatty acids
may act as metabolic inhibitors. 3HTA and 3HPA also increased state 4
respiration and decreased RCR, ΔΨm and mitochondrial NAD(P)H
content, implying that they also behave as uncouplers of oxidative
phosphorylation. These observations may possibly be related to the lac-
tic acidemia and mitochondrial morphological abnormalities observed
in tissues from patients affected by LCHAD deﬁciency [13,32]. We also
found that the ANT inhibitor ATC attenuated 3HTA-induced increase
of resting respiration (state 4), suggesting that ANT was involved in
this effect. In contrast, the UCP inhibitor GDP did not change this effect,
ruling out a role for UCP in the increase of resting respiration in the liver.
It is of note that UCP is poorly expressed in liver mitochondria and its
low expression in this tissue may possibly explain the reason by
which GDP did not prevent the effects elicited by the LCHFA [33].
However, considering that GDP was also unable to prevent the 3HTA-
induced reduction of membrane potential in brain mitochondria,
which express UCPs [33], it is conceivable that these UCPs were not
involved in the effects elicited by the LCHFA.
Uncoupling of oxidative phosphorylation had been previously
demonstrated for non-hydroxylated LCFA. The protonophoric mecha-
nism of this effect is thought to be due to the transbilayer movementFig. 6. Effects of 3-hydroxytetradecanodioic (3HTDA), 3-hydroxytetradecanoic (3HTA) and 3-h
were performed in a reaction media containing mitochondrial preparations (0.5 mg protein·
lines b–d) was added in the beginning of the assay. (B) 3HTA (10–30 μM, lines b–d), (C) 3HTA
the assay. (D) 3HTA (30 μM, lines b). Controls (lines a) were performed in the absence of fatt
after the beginning of the assay, as indicated. CCCP (3 μM)was added in the end of the assays. T
as ﬂuorescence arbitrary units (FAU).of undissociated (linked to protons) fatty acids through the mitochon-
drial inner membrane towards the mitochondrial matrix. The passage
of dissociated fatty acids in the opposite direction to the intermembrane
mitochondrial space is usually facilitated by ANT and UCP [34–37].
Although our ﬁndings demonstrated that ANT is involved in the
uncoupling effects of 3HTA and 3HPA, we cannot discard that LCFA
acid anions may also be transferred by other mitochondrial carriers,
such as the glutamate/aspartate antiporter [38,39], the mono- and tri-
carboxylate carriers [40] and the phosphate carrier [41].
Furthermore, 3HTA and 3HPA (10–30 μM), but not 3HTDA, strongly
dissipated ΔΨm in the presence of Ca2+. Furthermore, RR, a known in-
hibitor of themitochondrial Ca2+uniporter [42], and CsAplusADP, clas-
sical inhibitors of MPT, prevented ΔΨm dissipation, supporting a role
for Ca2+ and MPT induction in these effects. CsA is an inhibitor of MPT
by inactivating the cyclophilin D, amitochondrial matrix protein associ-
ated with the MPT occurrence [43–46], whereas ADP is a potent inhibi-
tor ofMPT in isolatedmitochondria by binding to ANT in thematrix side
[31,47]. We also found that neither the potent reducing agent DTT nor
the thiol group protector NEM avoided the ΔΨm loss, implying that
an oxidative attack to MPT pore was probably not involved in 3HTA-
induced MPT. In this regard, a common explanation for the induction
of nonselective permeabilization was the oxidation of membrane pro-
tein thiol groups on the MPT pore [48,49], but this was not the case
for these compounds, not supporting therefore a role for oxidative
damage in this effect.
3HTA and 3HPA (30 μM) also decreased mitochondrial matrix
NAD(P)H content after Ca2+ loading, which was totally abolished by
CsA plus ADP and by RR, implying that the decrease of matrix reduced
equivalents may have occurred as a consequence of nonselective
inner membrane permeabilization due to MPT. Alternatively, NADH
consumption due to MPT induction and consequent activation of the
electron transport ﬂow may have also contributed to the reduction of
NAD(P)H concentrations as observed here [48,50,51].
The nonselective permeabilization caused by MPT activation is usu-
ally accompanied by swelling and loss ofmitochondrial elements (Ca2+,
Mg2+, glutathione, NADH and NADPH), including pro-apoptotic factorsydroxypalmitic (3HPA) acids on mitochondrial Ca2+ retention capacity. All experiments
mL−1) supported by glutamate/malate or succinate. (A) 3HTDA, 3HTA or 3HPA (30 μM,
(30 μM, lines b–c) and cyclosporin A (CsA, 1 μM, line c) were added in the beginning of
y acids. All traces refer to mitochondrial preparations supplemented by 20 μM Ca2+ 50 s
races are representative of three independent experiments (animals) and were expressed
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as well as impairment of oxidative phosphorylation and ATP synthesis
[52–58]. In this regard,we demonstrated that 3HTA and 3HPAprovoked
extensive mitochondrial swelling after Ca2+ addition and this was
totally prevented by CsA and ADP, as well as by RR, conﬁrming the
occurrence of MPT.
Another important contribution of ourworkwas that themajor fatty
acids accumulated in LCHAD deﬁciency strongly compromised the ca-
pacity of mitochondria to uptake and retain Ca2+, which is a crucial
function of this organelle [59–63]. Again, this effect was totally
prevented by CsA, indicating that the reduction in mitochondrial Ca2+
retention capacity was a consequence of MPT induction. Indeed,
MPT pore opening could allow Ca2+ release from the matrix after
reaching a threshold, overcoming mitochondrial Ca2+ retention capacity
[52,55,57].
It is of interest that the effects found in our work were selective for
themonocarboxylic LCHFA, since the dicarboxylic 3HTDA, a structurally
analogue of 3HTA, did not alter any of the tested parameters. Noteworthy,
previous unpublished ﬁndings from our laboratory showed that the di-
carboxylic acids adipic, suberic and sebacic acids do not alter important
parameters of mitochondrial bioenergetics. A possible explanation for
the lack of effect of the dicarboxylates could be because they cannot
enter into mitochondrial matrix through the inner mitochondrial
membrane by diffusion, as possibly occurs with the monocarboxylic
analogues. In this context, monocarboxylic LCFA are in general good
protonophores (uncouplers), in contrast to dicarboxylic LCFA [64]. Fur-
thermore, it was postulated that the monocarboxylic LCFA have the abil-
ity to undergo ﬂip–ﬂopmovements in the phospholipid core of the inner
mitochondrial membrane and to be transported back to the intermem-
brane space by mitochondrial anion carriers in the anionic form [65].
Our present work shows that the signiﬁcant ﬁndings observed in
liver mitochondria were more pronounced and achieved with lower
doses of the LCHFA, as compared to brainmitochondria [24,26], indicat-
ing that liver is more vulnerable to the deleterious effects of these fatty
acids. It is therefore tempting to speculate that the higher vulnerability
of the liver to the effects of 3HTA and 3HPA on mitochondrial functions
may be possibly associated with the severe liver symptomatology, as
compared to the neurological manifestations, in patients with LCHAD
deﬁciency [11,14]. On the other hand, considering that fatty acid syn-
thesis and metabolism is very active in the liver, and besides that this
tissue essentially uses fatty acids for energy supply, it is conceivable
that the concentrations of these monocarboxylic hydroxylated fatty
acids in patients affected by LCHAD deﬁciency are much higher in the
liver, relatively to other tissues including the brain.
Regarding the mechanisms of LCHFA-induced MPT, it may have oc-
curred due to the uncoupling effects of 3HTA and 3HPA, which were
previously shown to provokeMPTpore opening [66–69].MPT induction
could be also consequent of the interaction of these fatty acids with the
cytosolic side of ANT, as previously demonstrated for ATC and other
similar compounds [70–72] since ATC attenuated state 4 increase.
We cannot at the present determine whether 3HTA and 3HPA bind
to albumin in the liver, since to the best of our knowledge there is no
work in the literature describing the interaction of long-chain hydroxyl-
ated fatty acid with albumin in various tissues. However, it is important
to emphasize that we used low albumin concentrations in the medium
similar to those found in liver cytosol to simulate an intracellular envi-
ronment [73]. Our results obtained under these experimental condi-
tions with low albumin concentration showed that 3HTA and 3HPA
caused signiﬁcant effects on the evaluated parameters, suggesting that
these fatty acids disturb mitochondrial energy homeostasis which may
be attributed to their free active unbinding form.
At the present it is difﬁcult to establish the pathophysiological rele-
vance of our data since the liver concentrations of free LCHFA in patients
affected by LCHAD deﬁciency are still unknown. However, it is conceiv-
able that theymay contribute to explain the pathophysiology of this dis-
ease since under experimental conditions that simulate an intracellularenvironment, the LCHFA that most accumulate in this disorder, particu-
larly 3HPA and 3HTA, reduced the ΔΨm and provoked mitochondrial
swelling in the presence of calcium that were prevented by CsA, ADP
and RR at similar or even lower concentrations (e.g.,: 10 μM) than
those found in plasma of the affected patients, especially during crises
of metabolic decompensation that are accompanied by a worsening of
hepatic clinical manifestations [3,74]. It is emphasized that these crises
generally follow infections and accelerated catabolism that leads to in-
creased tissue levels of these fatty acids [74].
5. Conclusions
In conclusion, to the best of our knowledge we provide for the ﬁrst
time experimental evidence that the monocarboxylic LCHFA that most
accumulate in LCHAD deﬁciency behave as strong metabolic inhibitors,
uncoupling agents andMPT inductors in the liver from young rats. Since
these effects might potentially reduce energy production, we propose
that disruption of mitochondrial homeostasis may be associated with
the hepatic failure presented by patients affected by LCHAD deﬁciency.
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